TruSight™ Oncology 500 Portfolio Updates

Improvements to enable a simpler, faster, and more scalable sample-to-results workflow for in-house comprehensive genomic profiling (CGP).

What’s new

Automation-friendly library prep

• ~50% less hands-on time with new kits and methods*
• Efficient scaling with reduced manual errors
• Qualified methods by Illumina and third-party vendors

Increased sequencing efficiency

• TruSight Oncology 500 High-Throughput and ctDNA are now compatible with the new NovaSeq™ 6000 v1.5 Reagent Kits
• Improved inventory management with extended reagents shelf-life (6 months)
• Reduced sequencing costs

Ultra-rapid variant calling

• On-premise and cloud-based variant calling software solution with the DRAGEN™ Bio-IT Platform† coming soon for the entire TruSight Oncology 500 Portfolio
• 2-10× faster analysis time, reducing overall time from sample to final interpretation report
• Streamlined variant calling workflow featuring simultaneous processing of data from large batches

* Applies to the TruSight Oncology 500 automation kits/methods available now, as well as TruSight Oncology 500 High-Throughput automation kits/methods available 1H 2021
† On-premise DRAGEN solution currently available for TruSight Oncology 500 ctDNA; on-premise and cloud-based solutions for the entire TruSight Oncology 500 portfolio coming soon

For Research Use Only. Not for use in diagnostic procedures.
Liquid biopsy pipeline enhancements

- Includes surrogate measurement for tumor fraction (maximum somatic allele fraction (MSAF))
- Provides improved sensitivity for the immuno-oncology biomarker microsatellite instability (MSI), now > 2400 sites

Streamlined, sample-to-results CGP workflow starting with tissue or liquid biopsy samples

### 4-5 days workflow

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Extraction</th>
<th>Library prep</th>
<th>Sequencing</th>
<th>Variant calling</th>
<th>Interpretation and reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>FFPE</td>
<td>DNA/RNA extraction kits</td>
<td>TruSight Oncology 500 Kit</td>
<td>NextSeq™ 550 or NextSeq 550Dx System² Up to 8 samples</td>
<td>DRAGEN platform (on-premise/cloud-based)² Local Docker Local Run Manager</td>
<td>Final Interpretation Report/PierianDx Clinical Genomics Workspace software</td>
</tr>
<tr>
<td>Blood</td>
<td>cfDNA extraction kits</td>
<td>TruSight Oncology 500 ctDNA Kit</td>
<td>NovaSeq 6000 System 8-24 samples</td>
<td>DRAGEN platform (on-premise/cloud-based)² Local Docker</td>
<td>Final Interpretation Report/PierianDx Clinical Genomics Workspace software</td>
</tr>
</tbody>
</table>

**Enable CGP from tissue biopsy**

**Enable CGP from liquid biopsy**

---

Learn more

For more information about the TruSight Oncology 500 Portfolio, visit [www.illumina.com/products/by-brand/trusight-oncology-500.html](http://www.illumina.com/products/by-brand/trusight-oncology-500.html)

Learn more about the powerful DRAGEN Bio-IT Platform at [www.illumina.com/DRAGEN](http://www.illumina.com/DRAGEN)